GtoPdb is requesting financial support from commercial users. Please see our sustainability page for more information.
| 
                               
                            
                                
                                                                Synonyms: BMY-13805 | BMY13805 | Exxua® | MJ-13805 | MJ13805 | ORG-13011 | Travivo (gepirone extended-release)
                                 
                                                         
                            
                            
                            
                                 
                                
                                gepirone is an approved drug (FDA (2023)) 
                                                        
                                                    
                                Compound class: 
                                                            Synthetic organic
                                 
                                
                                    
                                        Comment: Gepirone (BMY-13805) is a 5-HT1A receptor agonist [5].
                                    
                                 
                            
                            
                          
                                
                                    
                                
                          
                                   
                                   
                                  
                                      
                                     
                                   
                                   
                                    
                                    
                                     | 
                                    
                                        
                                         
  | 
                                    
                                
                                |||||||||||||||||||||||||||||||||||
| Bioactivity Comments | 
| The extended release formulation of gepirone has a short elimination half-life of ~6 hours [6]. Like buspirone it is converted to a pyrimidinepiperazin metabolite that acts as a potent α2-adrenoceptor antagonist [1]. Gepirone displaces [3H]8-OH-DPAT from human 5-HT1A receptors with a Ki of 13 nM [2]. |